Improvement of glycemic control by treatment for insomnia with suvorexant in type 2 diabetes mellitus

Toi, Norikazu; Inaba, Masaaki; Kurajoh, Masafumi; Morioka, Tomoaki; Hayashi, Noriyuki; Hirota, Tomoe; Miyaoka, Daichi; Emoto, Masanori; Yamada, Shinsuke

doi:10.1016/j.jcte.2018.12.006

Cited by 21 publications

(13 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Suvorexant is effective for the treatment of insomnia in patients with Alzheimer's disease, but whether it influences Alzheimer's disease itself remains unclear [69]. Suvorexant significantly increases sleep efficiency and decreases glucose levels in individuals with insomnia symptoms and type 2 diabetes mellitus, and these effects are consistent with the effects of suvorexant in an animal model [49,70]. Combination therapy with suvorexant and ramelteon improves subjective sleep quality without inducing delirium in acute stroke patients [71].…”

Section: Sleep Disorders Especially Primary Insomniamentioning

confidence: 87%

Orexin Receptor Antagonists as Emerging Treatments for Psychiatric Disorders

et al. 2019

View full text Add to dashboard Cite

Orexins comprise two neuropeptides produced by orexin neurons in the lateral hypothalamus and are released by extensive projections of these neurons throughout the central nervous system. Orexins bind and activate their associated G protein-coupled orexin type 1 receptors (OX1Rs) and OX2Rs and act on numerous physiological processes, such as sleep-wake regulation, feeding, reward, emotion, and motivation. Research on the development of orexin receptor antagonists has dramatically increased with the approval of suvorexant for the treatment of primary insomnia. In the present review, we discuss recent findings on the involvement of the orexin system in the pathophysiology of psychiatric disorders, including sleep disorders, depression, anxiety, and drug addiction. We discuss the actions of orexin receptor antagonists, including selective OX1R antagonists (SORA1s), selective OX2R antagonists (SORA2s), and dual OX1/2R antagonists (DORAs), in the treatment of these disorders based on both preclinical and clinical evidence. SORA2s and DORAs have more pronounced efficacy in the treatment of sleep disorders, whereas SORA1s may be promising for the treatment of anxiety and drug addiction. We also discuss potential challenges and opportunities for the application of orexin receptor antagonists to clinical interventions.

show abstract

Section: Sleep Disorders Especially Primary Insomniamentioning

confidence: 87%

Orexin Receptor Antagonists as Emerging Treatments for Psychiatric Disorders

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Although both short sleep duration and sleep quality have been associated with disease severity and insulin resistance in NAFLD, 12 the use of sleeping pills, regardless Open access of the drug type, has been shown to improve sleep quality and extend sleeping time. [27][28][29][30][31] On other hand, ramelteon, which is a melatonin receptor agonist, may be beneficial for NAFLD by repairing the circadian rhythm, which is associated with glucose metabolism and insulin sensitivity. 32 The effect of sleeping pills for preventing NAFLD may be worth examining.…”

Section: Discussionmentioning

confidence: 99%

Effects of sleep quality on non-alcoholic fatty liver disease: a cross-sectional survey

Takahashi

Anzai²,

Kuroda

et al. 2020

BMJ Open

View full text Add to dashboard Cite

BackgroundThe effects of sleep quality on the risk of developing non-alcoholic fatty liver disease (NAFLD) remain uncertain. The purpose of this study was to clarify the association between sleep quality and NAFLD.MethodsThe data of 4828 participants who underwent health check-ups at four hospitals were analysed. Sleep quality was evaluated by the Pittsburgh Sleep Quality Index (PSQI), which comprised seven elements scored from 0 to 3. The global PSQI score and the score for each element were compared between NAFLD and non-NAFLD groups separately by sex. Logistic regression analysis was performed to determine the association between NAFLD and each PSQI score.ResultsIn both men and women, the mean PSQI score for sleep medication use was significantly higher in non-NAFLD than in NAFLD. With regard to sleep medication use in men, the OR (95% CI) for NAFLD was lower with a score of 3 (OR 0.60, 95% CI 0.38–0.95) than with a score of 0 on multivariate logistic regression analysis adjusted for age, smoking habits and physical activity. The OR for NAFLD based on daytime dysfunction was also higher with a score of 3 than with a score of 0 in both men (OR 2.82, 95% CI 1.39–5.75) and women (OR 2.08, 95% CI 1.10–3.92). After adjustment for body mass index, the sleep latency scores in men and daytime dysfunction in women were associated with NAFLD.ConclusionSleep quality was associated with NAFLD, and there were sex differences.

show abstract

“…In addition, distorted sleep in patients with T2DM is linked with high nocturnal catecholamine causing early morning hyperglycemia. [ 42 ] Benzodiazepine improves sleep quality with a noteworthy reduction of sympathetic overactivity in patients with T2DM. Thus, benzodiazepine reduces insulin resistance and improves insulin sensitivity independent on benzodiazepine receptor activations.…”

Section: Methods and Search Strategymentioning

confidence: 99%